[go: up one dir, main page]

UY38339A - Inhibidores de las proteasas de serina del vhc derivados de prolinas macrocíclicas - Google Patents

Inhibidores de las proteasas de serina del vhc derivados de prolinas macrocíclicas

Info

Publication number
UY38339A
UY38339A UY0001038339A UY38339A UY38339A UY 38339 A UY38339 A UY 38339A UY 0001038339 A UY0001038339 A UY 0001038339A UY 38339 A UY38339 A UY 38339A UY 38339 A UY38339 A UY 38339A
Authority
UY
Uruguay
Prior art keywords
compounds
serine proteases
prolines
macrocyclic
inhibitors
Prior art date
Application number
UY0001038339A
Other languages
English (en)
Inventor
Yat Sun Or
Jun Ma
Guoqiang Wang
Jiang Long
Bin Wang
Original Assignee
Enanta Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45817947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY38339(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Enanta Pharm Inc filed Critical Enanta Pharm Inc
Publication of UY38339A publication Critical patent/UY38339A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • C07K5/123—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Compuestos de la fórmula I o sales, ésteres o prodrogas farmacéuticamente aceptables de los mismos: que inhiben la actividad de las proteasas de serina, en particular la actividad de la proteasa NS3-NS4A del virus de la hepatitis C (VHC). En consecuencia, los compuestos de la presente invención interfieren con el ciclo de vida del virus de la hepatitis C y también son útiles como agentes antivirales. Composiciones farmacéuticas que comprenden los compuestos mencionados para su administración a un sujeto que sufre de una infección por VHC. Métodos de tratamiento de una infección por VHC en un sujeto, mediante la administración de una composición farmacéutica que comprende los compuestos de la presente invención.
UY0001038339A 2010-09-21 2011-09-20 Inhibidores de las proteasas de serina del vhc derivados de prolinas macrocíclicas UY38339A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38505810P 2010-09-21 2010-09-21
US201161499994P 2011-06-22 2011-06-22
US201161504616P 2011-07-05 2011-07-05
UY0001033617A UY33617A (es) 2010-09-21 2011-09-20 Inhibidores de las proteasas de serina del vhc derivados de prolinas macrocíclicas

Publications (1)

Publication Number Publication Date
UY38339A true UY38339A (es) 2020-12-31

Family

ID=45817947

Family Applications (2)

Application Number Title Priority Date Filing Date
UY0001038339A UY38339A (es) 2010-09-21 2011-09-20 Inhibidores de las proteasas de serina del vhc derivados de prolinas macrocíclicas
UY0001033617A UY33617A (es) 2010-09-21 2011-09-20 Inhibidores de las proteasas de serina del vhc derivados de prolinas macrocíclicas

Family Applications After (1)

Application Number Title Priority Date Filing Date
UY0001033617A UY33617A (es) 2010-09-21 2011-09-20 Inhibidores de las proteasas de serina del vhc derivados de prolinas macrocíclicas

Country Status (42)

Country Link
US (7) US8648037B2 (es)
EP (2) EP2618831B1 (es)
JP (5) JP5857053B2 (es)
KR (5) KR20200117065A (es)
CN (2) CN104829688B (es)
AR (1) AR083052A1 (es)
AU (2) AU2011305695B2 (es)
BR (1) BR112013006693B1 (es)
CA (1) CA2812261C (es)
CL (2) CL2013000791A1 (es)
CO (1) CO6700835A2 (es)
CR (2) CR20180517A (es)
CY (2) CY1117113T1 (es)
DK (1) DK2618831T3 (es)
DO (2) DOP2013000062A (es)
EA (2) EA023009B1 (es)
EC (2) ECSP13012559A (es)
ES (1) ES2560003T3 (es)
GT (2) GT201300077AA (es)
HK (2) HK1223955A1 (es)
HR (1) HRP20160083T1 (es)
HU (2) HUE028384T2 (es)
IL (1) IL225412A (es)
LT (1) LTC2618831I2 (es)
LU (1) LUC00037I2 (es)
MX (3) MX343275B (es)
MY (1) MY164754A (es)
NL (1) NL300900I2 (es)
NO (2) NO2017056I2 (es)
NZ (2) NZ608720A (es)
PE (1) PE20140015A1 (es)
PL (1) PL2618831T3 (es)
PT (1) PT2618831E (es)
RS (1) RS54638B1 (es)
SG (1) SG188618A1 (es)
SI (1) SI2618831T1 (es)
SM (1) SMT201600100B (es)
TW (1) TWI523658B (es)
UA (1) UA116616C2 (es)
UY (2) UY38339A (es)
WO (1) WO2012040167A1 (es)
ZA (2) ZA201302317B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010132163A1 (en) * 2009-05-13 2010-11-18 Enanta Pharmaceuticals, Inc. Macrocyclic compounds as hepatitis c virus inhibitors
TW201119667A (en) * 2009-10-19 2011-06-16 Enanta Pharm Inc Bismacrocyclic compounds as hepatitis C virus inhibitors
UY38339A (es) 2010-09-21 2020-12-31 Enanta Pharm Inc Inhibidores de las proteasas de serina del vhc derivados de prolinas macrocíclicas
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
KR20150074051A (ko) 2012-10-19 2015-07-01 브리스톨-마이어스 스큅 컴퍼니 C형 간염 바이러스 억제제
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914598B1 (en) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9580463B2 (en) 2013-03-07 2017-02-28 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
LT3213750T (lt) * 2013-03-14 2020-10-26 Abbvie Inc. Dviejų antivirusinių vaistų derinys hepatitui c gydyti
US20200368229A9 (en) * 2013-03-14 2020-11-26 Abbvie Inc. Methods for Treating HCV
LT2968302T (lt) 2013-03-14 2017-12-27 Abbvie Inc. Tiesioginio poveikio antivirusinių agentų ir ribavirino derinys, skirtas hvc sergančių pacientų gydymui
WO2015153792A1 (en) * 2014-04-02 2015-10-08 Abbvie Inc. Methods for treating hcv
US20180042982A1 (en) * 2013-03-14 2018-02-15 Abbvie Inc. Methods for Treating HCV
CN105073758B (zh) 2013-03-15 2017-08-11 吉利德科学公司 丙型肝炎病毒抑制剂
WO2015061742A2 (en) * 2013-10-25 2015-04-30 Abbvie, Inc. Methods for treating hcv
JP6425727B2 (ja) * 2013-12-23 2018-11-21 ギリアード サイエンシーズ， インコーポレイテッド 大環状ｈｃｖ ｎｓ３阻害トリペプチド
WO2015100144A1 (en) * 2013-12-23 2015-07-02 Gilead Sciences, Inc. Crystalline forms of a macrocyclic hcv ns3 inhibiting tripeptide
EP2899207A1 (en) 2014-01-28 2015-07-29 Amikana.Biologics New method for testing HCV protease inhibition
EP3125889A1 (en) * 2014-04-02 2017-02-08 AbbVie Inc. Methods for treating hcv
EP3151850A4 (en) * 2014-06-06 2017-11-29 AbbVie Inc. Crystal forms
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
US9809576B1 (en) 2014-07-18 2017-11-07 Abbvie Inc. Synthetic route to anti-viral agents
US9809534B1 (en) 2014-07-21 2017-11-07 Abbvie Inc. Difluoroalkylcyclopropyl amino acids and esters, and syntheses thereof
US10059969B1 (en) 2014-10-03 2018-08-28 Abbvie Inc. Process for the preparation of (S)-2-amino-non-8-enoic acid
US10316338B1 (en) 2015-01-30 2019-06-11 Abb Vie Inc. Enzymatic process for the preparation of (1S,2R)-2-(difluoromethyl)-1-(propoxycarbonyl)cyclopropanecarboxylic acid
WO2016134058A1 (en) 2015-02-18 2016-08-25 Abbvie Inc. Combinations useful to treat hepatitis c virus
CA2990855A1 (en) * 2015-06-26 2016-12-29 Abbvie Inc. Solid pharmaceutical compositions for treating hcv
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
BR112018000383A2 (pt) 2015-07-08 2018-09-18 Abbvie Inc métodos para tratar hcv
IL256945B2 (en) * 2015-07-17 2023-10-01 Abbvie Inc Solid pharmaceutical compositions comprising a combination of two compounds for treating hepatitis c virus infection
KR101726567B1 (ko) 2016-07-08 2017-04-13 박공영 수직형 식물 재배장치
CN110461812A (zh) 2017-02-01 2019-11-15 艾伯维公司 用于制备(±)-2-(二氟甲基)-1-(烷氧基羰基)-环丙烷甲酸和(±)-2-(乙烯基)-1-(烷氧基羰基)-环丙烷甲酸的酶促方法
JP2018131439A (ja) 2017-02-14 2018-08-23 アッヴィ・インコーポレイテッド Ｈｃｖを処置する方法
CA2981993A1 (en) * 2017-08-02 2019-02-02 Abbvie Inc. Methods for treating hcv
US20200330460A1 (en) * 2017-09-01 2020-10-22 Abbvie Inc. Methods for Treating HCV
EP3694512A1 (en) 2017-10-12 2020-08-19 Abbvie Inc. Methods for treating hcv
WO2019084740A1 (zh) * 2017-10-31 2019-05-09 上海同昌生物医药科技有限公司 一种Glecaprevir合成中间体及其胺盐的制备方法
CN107739319A (zh) * 2017-10-31 2018-02-27 上海同昌生物医药科技有限公司 一种Glecaprevir合成中间体及其胺盐的制备方法
CN108329332A (zh) * 2018-03-16 2018-07-27 安徽华昌高科药业有限公司 一种制备Glecaprevir的方法
CA3136316A1 (en) 2019-04-08 2020-10-15 Abbvie Inc. Solid pharmaceutical compositions for treating hcv
KR102681664B1 (ko) 2019-06-12 2024-07-05 엘지디스플레이 주식회사 폴더블 디스플레이와 그 구동 방법
WO2021137256A1 (en) 2020-01-03 2021-07-08 Mylan Laboratories Limited Polymorphic forms of glecaprevir
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors
CN114085458A (zh) * 2021-12-08 2022-02-25 宁波塑之华塑化有限公司 一种高强度高韧性阻燃聚丙烯复合材料及其制备方法

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0100100A3 (en) 1997-08-11 2001-12-28 Boehringer Ingelheim Ca Ltd Hepatitis c inhibitor peptide analogues, pharmaceutical compositions comprising thereof and their use
JP4354632B2 (ja) 1997-08-11 2009-10-28 ベーリンガー インゲルハイム （カナダ） リミテッド Ｃ型肝炎抑制剤ペプチド
EA200700564A1 (ru) 1998-02-25 2007-08-31 Эмори Юниверсити 2`-фторнуклеозиды
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
CA2389745C (en) 1999-11-04 2010-03-23 Shire Biochem Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
ID30204A (id) 1999-12-27 2001-11-15 Japan Tobacco Inc Senyawa-senyawa cincin terfusi dan penggunaannya sebagai obat
CN1427722A (zh) 2000-02-18 2003-07-02 希拉生物化学股份有限公司 用核苷类似物治疗或预防黄病毒感染的方法
WO2001077113A2 (en) 2000-04-05 2001-10-18 Schering Corporation Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
MXPA03004299A (es) 2000-11-20 2004-02-12 Bristol Myers Squibb Co Inhibidores de tripeptido de hepatitis c.
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
JP4558314B2 (ja) 2001-07-20 2010-10-06 ベーリンガー インゲルハイム （カナダ） リミテッド ウイルスポリメラーゼインヒビター
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
EP1429759A4 (en) 2001-09-26 2004-12-15 Bristol Myers Squibb Co COMPOUNDS FOR TREATING HEPATITIS C VIRUS
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
CA2369711A1 (en) 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
CA2370396A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
CA2369970A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
PL213029B1 (pl) 2002-05-20 2012-12-31 Bristol Myers Squibb Co Podstawiona pochodna cykloalkilowa, zawierajaca ja kompozycja oraz ich zastosowanie
JP4312718B2 (ja) 2002-05-20 2009-08-12 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルス阻害剤
DE60334205D1 (en) 2002-05-20 2010-10-28 Bristol Myers Squibb Co Heterocyclische sulfonamid-hepatitis-c-virus-hemmer
ATE389656T1 (de) 2002-06-04 2008-04-15 Neogenesis Pharmaceuticals Inc Pyrazolo(1,5-a)pyrimidin-verbindungen als antivirale agentien
US20040138109A1 (en) 2002-09-30 2004-07-15 Boehringer Ingelheim Pharmaceuticals, Inc. Potent inhibitor of HCV serine protease
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US20050159345A1 (en) 2002-10-29 2005-07-21 Boehringer Ingelheim International Gmbh Composition for the treatment of infection by Flaviviridae viruses
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7098231B2 (en) 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
CN1771050A (zh) 2003-02-07 2006-05-10 益安药业 丙型肝炎丝氨酸蛋白酶的大环抑制剂
JP4550824B2 (ja) 2003-03-05 2010-09-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎抑制化合物
ES2354282T3 (es) 2003-03-05 2011-03-11 Boehringer Ingelheim International Gmbh Análogos peptídicos inhibidores de la hepatitis c.
GB0307891D0 (en) 2003-04-04 2003-05-14 Angeletti P Ist Richerche Bio Chemical compounds,compositions and uses
ES2386161T3 (es) 2003-04-16 2012-08-10 Bristol-Myers Squibb Company Proceso para separar una mezcla de enantiómeros de éster alquílico usando una enzima
US7176208B2 (en) 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
DK1615613T3 (da) 2003-04-18 2010-03-22 Enanta Pharm Inc Quinoxalinyl-makrocykliske hepatitis C serin protease-inhibitorer
WO2004103996A1 (en) 2003-05-21 2004-12-02 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
WO2004113365A2 (en) 2003-06-05 2004-12-29 Enanta Pharmaceuticals, Inc. Hepatitis c serine protease tri-peptide inhibitors
US7125845B2 (en) 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
KR20060054410A (ko) 2003-08-01 2006-05-22 제네랩스 테크놀로지스, 인코포레이티드 플라비비리다에에 대한 2고리 이미다졸 유도체
WO2005014543A1 (ja) 2003-08-06 2005-02-17 Japan Tobacco Inc. 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
MXPA06003141A (es) 2003-09-22 2006-06-05 Boehringer Ingelheim Int Peptidos macrociclicos activos contra el virus de la hepatitis c.
KR100853579B1 (ko) 2003-10-14 2008-08-21 인터뮨, 인크. Ｈｃｖ 복제 억제제로서 거대고리 카르복실산 및아실술폰아미드
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP1688420A4 (en) 2003-11-19 2008-10-22 Japan Tobacco Inc 5-5 LOW-CONDENSED HETEROCYCLIC COMPOUND AND THEIR USE AS HCV POLYMERASE INHIBITOR
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7309708B2 (en) 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
CA2546290A1 (en) 2003-11-20 2005-06-09 Schering Corporation Depeptidized inhibitors of hepatitis c virus ns3 protease
WO2005070955A1 (en) 2004-01-21 2005-08-04 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis c virus
KR20120091276A (ko) 2004-02-20 2012-08-17 베링거 인겔하임 인터내셔날 게엠베하 바이러스 폴리머라제 억제제
US7705146B2 (en) 2004-06-28 2010-04-27 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor peptide analogs
PE20060569A1 (es) 2004-07-16 2006-06-22 Boehringer Ingelheim Int Compuestos de indol carbonilamino como inhibidores de la polimerasa ne5b del vhc
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
JP4914355B2 (ja) 2004-07-20 2012-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎インヒビターペプチド類似体
EP1879607B1 (en) * 2005-05-02 2014-11-12 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
US7470664B2 (en) 2005-07-20 2008-12-30 Merck & Co., Inc. HCV NS3 protease inhibitors
MX2008001166A (es) * 2005-07-25 2008-03-18 Intermune Inc Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c.
WO2007016441A1 (en) 2005-08-01 2007-02-08 Merck & Co., Inc. Macrocyclic peptides as hcv ns3 protease inhibitors
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
PE20080992A1 (es) 2006-06-26 2008-08-06 Enanta Pharm Inc Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c
US7635683B2 (en) 2006-08-04 2009-12-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl tripeptide hepatitis C virus inhibitors
US7582605B2 (en) 2006-08-11 2009-09-01 Enanta Pharmaceuticals, Inc. Phosphorus-containing hepatitis C serine protease inhibitors
WO2008051475A2 (en) 2006-10-24 2008-05-02 Merck & Co., Inc. Hcv ns3 protease inhibitors
CA2667266C (en) 2006-10-24 2015-11-24 Merck & Co., Inc. Hcv ns3 protease inhibitors
CA2667165A1 (en) 2006-10-24 2008-05-02 Merck & Co., Inc. Hcv ns3 protease inhibitors
EP2086982B1 (en) 2006-10-27 2018-08-29 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
EP2083844B1 (en) 2006-10-27 2013-11-27 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
US8377872B2 (en) 2007-04-26 2013-02-19 Enanta Pharmaceuticals, Inc. Cyclic P3 tripeptide hepatitis C serine protease inhibitors
US20080267917A1 (en) 2007-04-26 2008-10-30 Deqiang Niu N-functionalized amides as hepatitis c serine protease inhibitors
WO2008134397A1 (en) 2007-04-26 2008-11-06 Enanta Pharmaceuticals, Inc. Aza-tripeptide hepatitis c serine protease inhibitors
CA2699891C (en) 2007-07-19 2013-10-22 Nigel Liverton Macrocyclic compounds as antiviral agents
US8383583B2 (en) 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
EP2219454A4 (en) 2007-11-14 2012-05-30 Enanta Pharm Inc HEMMER OF MACROCYCLIC TETRAZOLYL HEPATITIS C SERIN PROTEASE
CL2008003384A1 (es) * 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
CA2708042A1 (en) 2007-12-05 2009-06-11 Enanta Pharmaceuticals, Inc. Quinoxalinyl derivatives
JP5529036B2 (ja) 2007-12-05 2014-06-25 エナンタ ファーマシューティカルズ インコーポレイテッド フッ素化トリペプチドｈｃｖセリンプロテアーゼ阻害剤
WO2009079353A1 (en) 2007-12-14 2009-06-25 Enanta Pharmaceuticals, Inc. Triazole-containing macrocyclic hcv serine protease inhibitors
CA2709089A1 (en) 2007-12-14 2009-06-25 Enanta Pharmaceuticals, Inc. Macrocyclic oximyl hepatitis c serine protease inhibitors
US8283309B2 (en) 2007-12-20 2012-10-09 Enanta Pharmaceuticals, Inc. Bridged carbocyclic oxime hepatitis C virus serine protease inhibitors
US8591878B2 (en) * 2008-02-25 2013-11-26 Merck Sharp & Dohme Corp. Therapeutic compounds
WO2009117594A1 (en) 2008-03-20 2009-09-24 Enanta Pharmaceuticals, Inc. Fluorinated macrocyclic compounds as hepatitis c virus inhibitors
JP2011518882A (ja) 2008-04-28 2011-06-30 メルク・シャープ・エンド・ドーム・コーポレイション Ｈｃｖｎｓ３プロテアーゼ阻害剤
US8211891B2 (en) 2008-04-30 2012-07-03 Enanta Pharmaceuticals, Inc. Difluoromethyl-containing macrocyclic compounds as hepatitis C virus inhibitors
EP2540349B1 (en) * 2008-07-22 2014-02-12 Merck Sharp & Dohme Corp. Pharmaceutical compositions comprising a macrocyclic quinoxaline compound which is an hcv ns3 protease inhibitor
WO2010132163A1 (en) * 2009-05-13 2010-11-18 Enanta Pharmaceuticals, Inc. Macrocyclic compounds as hepatitis c virus inhibitors
EP2459582B1 (en) 2009-07-30 2015-05-27 Merck Sharp & Dohme Corp. Hepatitis c virus ns3 protease inhibitors
TW201119667A (en) 2009-10-19 2011-06-16 Enanta Pharm Inc Bismacrocyclic compounds as hepatitis C virus inhibitors
UY38339A (es) 2010-09-21 2020-12-31 Enanta Pharm Inc Inhibidores de las proteasas de serina del vhc derivados de prolinas macrocíclicas
US20130178413A1 (en) 2010-09-21 2013-07-11 John A. McCauley Hcv ns3 protease inhibitors

Also Published As

Publication number Publication date
EP2618831A1 (en) 2013-07-31
ECSP19072215A (es) 2019-10-31
ZA201302317B (en) 2014-09-25
CR20130135A (es) 2013-10-04
JP2016104756A (ja) 2016-06-09
JP2021063130A (ja) 2021-04-22
US20170088583A1 (en) 2017-03-30
US20160145298A1 (en) 2016-05-26
MY164754A (en) 2018-01-30
ZA201308655B (en) 2014-11-26
JP2020015730A (ja) 2020-01-30
PL2618831T3 (pl) 2016-06-30
NZ608720A (en) 2015-03-27
MX2019013037A (es) 2020-02-05
CA2812261C (en) 2017-02-21
AU2011305695B2 (en) 2016-05-19
RS54638B1 (en) 2016-08-31
BR112013006693A2 (pt) 2016-06-14
JP5857053B2 (ja) 2016-02-10
JP2013538235A (ja) 2013-10-10
IL225412A0 (en) 2013-06-27
TW201216979A (en) 2012-05-01
CR20180517A (es) 2018-12-06
EA201500728A2 (ru) 2016-03-31
US20190263860A1 (en) 2019-08-29
KR20190069623A (ko) 2019-06-19
US8648037B2 (en) 2014-02-11
EA029145B1 (ru) 2018-02-28
MX2013003230A (es) 2013-10-17
CN104829688A (zh) 2015-08-12
KR101894704B1 (ko) 2018-09-05
SMT201600100B (it) 2016-04-29
KR20130098369A (ko) 2013-09-04
UA116616C2 (uk) 2018-04-25
CL2014000612A1 (es) 2014-09-05
CA2812261A1 (en) 2012-03-29
CN103209703A (zh) 2013-07-17
DOP2013000062A (es) 2013-07-15
SI2618831T1 (sl) 2016-06-30
NZ703416A (en) 2016-06-24
AR083052A1 (es) 2013-01-30
JP2018162265A (ja) 2018-10-18
IL225412A (en) 2017-02-28
HUE028384T2 (en) 2016-12-28
EA201390425A1 (ru) 2013-09-30
LTC2618831I2 (lt) 2021-11-10
CN103209703B (zh) 2015-05-27
US20120070416A1 (en) 2012-03-22
UY33617A (es) 2012-07-31
US20140194350A1 (en) 2014-07-10
LTPA2017034I1 (lt) 2017-11-10
NO2017056I2 (no) 2018-11-26
CN104829688B (zh) 2021-02-09
MX369246B (es) 2019-11-01
HUS1700039I1 (hu) 2017-11-28
SG188618A1 (en) 2013-04-30
HK1186979A1 (zh) 2014-03-28
AU2016204491A1 (en) 2016-07-21
ES2560003T3 (es) 2016-02-17
HRP20160083T1 (hr) 2016-02-26
EP2618831B1 (en) 2016-01-06
DOP2019000218A (es) 2019-09-15
NO2021040I1 (no) 2021-09-16
PE20140015A1 (es) 2014-02-16
JP6574023B2 (ja) 2019-09-11
WO2012040167A1 (en) 2012-03-29
KR20200117065A (ko) 2020-10-13
KR102163902B1 (ko) 2020-10-12
LUC00037I1 (es) 2017-10-12
KR20190110648A (ko) 2019-09-30
BR112013006693B1 (pt) 2022-07-12
CY2017033I1 (el) 2018-04-04
US20180162905A1 (en) 2018-06-14
US20200270303A1 (en) 2020-08-27
KR20180099929A (ko) 2018-09-05
US9220748B2 (en) 2015-12-29
NL300900I2 (nl) 2017-11-16
KR102128232B1 (ko) 2020-06-30
KR101990279B1 (ko) 2019-06-19
CL2013000791A1 (es) 2013-07-12
DK2618831T3 (en) 2016-04-04
PT2618831E (pt) 2016-03-04
CY1117113T1 (el) 2017-04-05
TWI523658B (zh) 2016-03-01
MX343275B (es) 2016-10-31
LUC00037I2 (es) 2017-12-13
HK1223955A1 (zh) 2017-08-11
ECSP13012559A (es) 2014-05-31
CY2017033I2 (el) 2018-04-04
EP3020723A1 (en) 2016-05-18
CO6700835A2 (es) 2013-06-28
EA023009B1 (ru) 2016-04-29
GT201300077A (es) 2014-12-16
AU2011305695A1 (en) 2013-04-11
GT201300077AA (es) 2019-11-13
NO2017056I1 (no) 2017-11-10
EP2618831A4 (en) 2014-11-19
JP6352238B2 (ja) 2018-07-04
EA201500728A3 (ru) 2016-07-29

Similar Documents

Publication Publication Date Title
DOP2019000218A (es) Inhibidores de las proteasas de serina del vhc derivados de prolinas macrocíclicas
CO6280441A2 (es) Compuestos que contienen quinoxalina como inhibidores del virus de la hepatitis c
ECSP077648A (es) Tetrazolilos macrociclicos como inhibidores de serina proteasa de hepatitis c
UY30392A1 (es) Compuestos de oximilo macrociclico inhibidores de proteasa de hepatitis c
ECSP077649A (es) Piridazinonilos macrociclicos como inhibidores de serina proteasa de hepatitis c
UY30437A1 (es) Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c
UY30391A1 (es) Compuesto de oximilo aciclico inhibidores de proteasa de hepatitis c
ECSP12012067A (es) Inhibidores del virus de la hepatitis c
MX2010010276A (es) Compuestos macrociclicos fluorinados como inhibidores del virus de hepatitis c.
MX2011012155A (es) Compuestos macrociclicos como inhibidores del virus de hepatitis c.
MX2010006518A (es) Inhibidores de serina proteasa de hepatitis c de oximil macrociclica.
ECSP12012104A (es) Inhibidores de virus flaviviridae
MX2010006210A (es) Inhibidores de serina proteasa de hcv de tripeptido fluorado.
EP2555622A4 (en) HEPATITIS C-VIRUS HEMMER
MX2010008109A (es) Tripéptidos difluorizados como inhibidores de proteasa de serina de virus de hepatitis c (hcv).
WO2011049908A3 (en) Bismacrokyclic compounds as hepatitis c virus inhibitors
MX2010008108A (es) Inhibidores de proteasa de serina de tripéptido de virus de hepatitis c (hcv) que contienen heteroarilo.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20210909